PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of PepGen, Inc. (NASDAQ:PEPG) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $12.60.

PEPG has been the subject of a number of analyst reports. Oppenheimer began coverage on PepGen in a research report on Wednesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. Guggenheim lifted their price target on shares of PepGen from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a report on Thursday, January 22nd.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PEPG. RA Capital Management L.P. raised its holdings in shares of PepGen by 87.7% in the third quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock valued at $92,698,000 after buying an additional 9,375,000 shares during the last quarter. Viking Global Investors LP increased its position in PepGen by 134.9% in the 3rd quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock valued at $16,089,000 after acquiring an additional 2,000,000 shares during the period. Commodore Capital LP increased its position in PepGen by 44.2% in the 4th quarter. Commodore Capital LP now owns 3,400,000 shares of the company’s stock valued at $22,134,000 after acquiring an additional 1,042,681 shares during the period. Vivo Capital LLC purchased a new stake in PepGen during the 3rd quarter valued at approximately $10,742,000. Finally, Laurion Capital Management LP raised its stake in PepGen by 8.5% during the 4th quarter. Laurion Capital Management LP now owns 2,052,133 shares of the company’s stock valued at $13,359,000 after acquiring an additional 159,977 shares during the last quarter. 58.01% of the stock is owned by hedge funds and other institutional investors.

PepGen Stock Performance

PEPG opened at $5.12 on Thursday. The stock has a market capitalization of $353.84 million, a PE ratio of -2.12 and a beta of 1.87. PepGen has a one year low of $0.88 and a one year high of $7.80. The business’s 50 day moving average price is $5.75 and its 200 day moving average price is $5.00.

PepGen (NASDAQ:PEPG) last posted its earnings results on Wednesday, March 4th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.13. As a group, equities research analysts forecast that PepGen will post -2.73 earnings per share for the current fiscal year.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).